Head to head
Thermo Fisher Scientific vs Danaher
Side-by-side on the measures that matter, with a plain-English read. Full detail: TMO · DHR
TMO
Thermo Fisher Scientific
658.02+0.93%
1-year price shape — +23% over the period
Quant Rating C · 64/100
vs
DHR
Danaher
219.81+1.08%
1-year price shape — +8% over the period
Quant Rating C · 49/100
1-year performance, rebased to 100
Danaher edges it on the scoreable measures. Danaher pays the highest dividend yield.
| TMO | DHR | |
|---|---|---|
| Snapshot | ||
| Sector | Diagnostics & Research | Diagnostics & Research |
| Last price | 658.02 | 219.81 |
| Change today | +0.93% | +1.08% |
| 1-year return | +23.4% | +8.1% |
| Market cap | $243.30B | $154.52B |
| 52-week range | 434.50 – 694.33 | 160.31 – 241.35 |
| Valuation | ||
| P/E (TTM) | 35.42 | 39.04 |
| P/E percentile, own 5-yr range | 86th | 64th |
| P/B | 4.62 | 2.94 |
| Dividend yield | 0.27% | 0.66% |
| Profitability & growth | ||
| EPS (TTM) | 17.74 | 5.05 |
| Net profit (TTM) | $6.56B | $3.55B |
| Revenue (TTM) | $46.34B | $25.11B |
| Revenue growth (YoY) | +10.5% | +5.5% |
| Gross margin | 40.8% | 58.5% |
| Operating margin | 18.3% | 20.4% |
| Net margin | 15.0% | 15.9% |
| Free cash flow (TTM) | $7.32B | $5.47B |
| Ownership & sentiment | ||
| Institutional ownership | 92.8% | 83.9% |
| Insider activity (12mo) | 22 buy / 28 sell | 38 buy / 6 sell |
| Short interest (% of float) | 1.5% | 1.3% |
| Analyst consensus | 88% buy / 12% hold (16) | 94% buy / 6% hold (17) |
| Analyst price target | $673 (+2%) | $233 (+6%) |
| StockVane view | ||
| StockVane Quant Rating | C (64) | C (49) |
| Company | ||
| Employees | 125,000 | 60,000 |
| Founded | 1956 | 1984 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.